Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Trowbridge

Showing results (141-150 of 143) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 143 results.
Cell Reports. Medicine|January 27, 2026
An encyclopedia of the cord blood metabolome reveals maternal-fetal interactions and disease riskSamuel Lancaster, Samson Mataraso, Jonathan D Reiss, et al.
Cancers|August 30, 2020
Systems Biology Approach Identifies Prognostic Signatures of Poor Overall Survival and Guides the Prioritization of Novel BET-CHK1 Combination Therapy for OsteosarcomaPankita H Pandya, Lijun Cheng, M Reza Saadatzadeh, et al.
Neoplasia (New York, N.Y.)|January 16, 2026
Dual CDK4/6-PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcomaFarinaz Barghi, M Reza Saadatzadeh, Erika A Dobrota, et al.
Pageof 15

Showing results (141-150 of 143) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 143 results.
Cell Reports. Medicine|January 27, 2026
An encyclopedia of the cord blood metabolome reveals maternal-fetal interactions and disease riskSamuel Lancaster, Samson Mataraso, Jonathan D Reiss, et al.
Cancers|August 30, 2020
Systems Biology Approach Identifies Prognostic Signatures of Poor Overall Survival and Guides the Prioritization of Novel BET-CHK1 Combination Therapy for OsteosarcomaPankita H Pandya, Lijun Cheng, M Reza Saadatzadeh, et al.
Neoplasia (New York, N.Y.)|January 16, 2026
Dual CDK4/6-PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcomaFarinaz Barghi, M Reza Saadatzadeh, Erika A Dobrota, et al.
Pageof 15